País: África do Sul
Língua: inglês
Origem: South African Health Products Regulatory Authority (SAHPRA)
Bayer
CIPROBAY® 250, 500, 750 (Tablets) CIPROBAY® IV (Infusion) CIPROBAY® Suspension 5% SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CIPROBAY ® 250, 500, 750 (Tablets) CIPROBAY ® IV (Infusion) CIPROBAY ® Suspension 5% COMPOSITION: CIPROBAY 250tablet contains 291 mg ciprofloxacin hydrochloride monohydrate, equivalent to 250 mg ciprofloxacin. CIPROBAY 500tablet contains 582 mg ciprofloxacin hydrochloride monohydrate, equivalent to 500 mg ciprofloxacin. CIPROBAY 750tablet contains 873 mg ciprofloxacin hydrochloride monohydrate, equivalent to 750 mg ciprofloxacin. CIPROBAY IVcontains 2,54 mg ciprofloxacin lactate equivalent to 2,0 mg ciprofloxacin per mL in 0,9% sodium chloride solution. CIPROBAY Suspension 5% when reconstituted as directed with the suspension diluent, each 5 mL CIPROBAY Suspension 5% contains ciprofloxacin microcapsules equivalent to 250 mg ciprofloxacin. PHARMACOLOGICAL CLASSIFICATION: A. 20.1.1. Broad and medium spectrum antibiotics. PHARMACOLOGICAL ACTION: Ciprofloxacin is a synthetic, 4-quinolone derivative with in vitrobactericidal activity against the following Gram- negative and Gram-positive organisms. In vitrosensitivity does not necessarily imply in vivoefficacy. Acinetobacter Haemophilus influenzae Proteus vulgaris Streptococcus pyogenes Aeromonas Haemophilus para-influenzae Providencia rettgeri Streptococcus species Brucella Hafnia Providencia stuartii Vibrio Campylobacter jejuni Klebsiella species Pseudomonas aeruginosa Viridans streptococci Citrobacter freundii Listeria Salmonella enteritidis Yersinia Citrobacter species Moraxella catarrhalis Serratia marcescens Corynebacterium Morganella morganii Shigella flexneri E. coli Neisseria gonorrhoeae Shigella sonnei Edwardsiella Pasteurella Staphyloccocus aureus Enterobacter cloacae Plesiomonas Staphylococcus epidermidis Enterobacter species Proteus mirabi Leia o documento completo